Cost-effectiveness of lutetium (177Lu) oxodotreotide vs everolimus in gastroenteropancreatic neuroendocrine tumors in Norway and Sweden

doi:10.12998/wjcc.v8.i20.4793

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 20

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5589)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-5) series.

Item

Count

PDF

284

WORD

224

HTML

3471

Figures (1-2)

197

Tables (1-5)

221

Sum=4397

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

539

Download

653

Sum=1192

Oct 26, 2020 (publication date) through Nov 4, 2024

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Clin Cases. Oct 26, 2020; 8(20): 4793-4806
Published online Oct 26, 2020. doi: 10.12998/wjcc.v8.i20.4793

Table 2 Utilities used in the base case analysis

Health state	Utility (SE)	Source
Sweden
Midgut-NET progression-free survival	0.79 (0.01)	Real world evidence¹
Midgut-NET post-progression survival	0.74 (0.01)	ERASMUS study²
P-NET progression-free survival	0.80 (0.01)	ERASMUS study²
P-NET post-progression survival	0.79 (0.02)	ERASMUS study²
Norway
Midgut-NET progression-free survival (Lutathera)	0.75 (0.01)	NETTER-1[13]
Midgut-NET post-progression survival	0.74 (0.01)	ERASMUS study²
P-NET progression-free survival	0.80 (0.01)	ERASMUS study²
P-NET post-progression survival	0.79 (0.02)	ERASMUS study²

¹Real world study conducted at Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom (AAA, data on file).

²AAA data on file. Midgut-NET: Midgut neuroendocrine tumor; P-NET: Pancreatic neuroendocrine tumor; SE: Standard error.

Citation: Palmer J, Leeuwenkamp OR. Cost-effectiveness of lutetium (¹⁷⁷Lu) oxodotreotide vs everolimus in gastroenteropancreatic neuroendocrine tumors in Norway and Sweden. World J Clin Cases 2020; 8(20): 4793-4806
URL: https://www.wjgnet.com/2307-8960/full/v8/i20/4793.htm
DOI: https://dx.doi.org/10.12998/wjcc.v8.i20.4793